Bio-Rad LaboratoriesBIO.B +2.24%71 OCF Margin % is 18.26% as of Mar. 2026, which is 15% above its 10-year median of 15.89. GuruFocus rates BIO.B with a GF Score™ of 71/100 and a GF Value™ of $317.48 (Fairly Valued). The stock has 4 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Bio-Rad Laboratories ranks better than 78.04% on this metric.
The historical rank and industry rank for Bio-Rad Laboratories's OCF Margin % or its related term are showing as below:
BIO.B'
s OCF Margin % Range Over the Past 10 Years
Min: 4.82 Med: 15.89 Max: 22.98
Current: 19.71
During the past 13 years, the highest OCF Margin % of Bio-Rad Laboratories was 22.98%. The lowest was 4.82%. And the median was 15.89%.
BIO.B's OCF Margin % is ranked better than 78.04% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: 5.86
vs BIO.B: 19.71
Bio-Rad Laboratories OCF Margin % Related Terms
Bio-Rad Laboratories OCF Margin % Historical Data
* Premium members only.
The historical data trend for Bio-Rad Laboratories's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BIO.B vs BRKR, MASI, PODD: OCF Margin % Comparison
For the Medical Devices subindustry, Bio-Rad Laboratories's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Rad Laboratories OCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Bio-Rad Laboratories's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Rad Laboratories (BIO.B) has a OCF Margin % of 18.26% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Bio-Rad Laboratories and its competitors. This is 15% above median its historical median of 15.89. Over the past decade, Bio-Rad Laboratories' OCF Margin % has ranged from 4.82 to 22.98. According to the industry distribution chart, Bio-Rad Laboratories ranks #179 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 22%.
Is Bio-Rad Laboratories' OCF Margin % too high?
Bio-Rad Laboratories' current OCF Margin % of 18.26% is 15% above median its 10-year median of 15.89. Over the past 10 years, this metric has ranged from a low of 4.82 to a high of 22.98. The Medical Devices & Instruments industry median OCF Margin % is 5.86. Bio-Rad Laboratories' value of 18.26% is 211.6% above this industry median. Based on the distribution chart, Bio-Rad Laboratories ranks #179 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bio-Rad Laboratories has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' OCF Margin % compare to BRKR and MASI?
According to the Medical Devices & Instruments industry distribution chart, Bio-Rad Laboratories ranks #179 out of 815 companies for OCF Margin %. This places Bio-Rad Laboratories in the top 22% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 5.86. Bio-Rad Laboratories' value of 18.26% is 211.6% above this benchmark. Historically, Bio-Rad Laboratories' own OCF Margin % has ranged from 4.82 to 22.98 over the past decade. While the company's 10-year median is 15.89 vs. the industry median of 5.86, Bio-Rad Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 5.86, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Rad Laboratories's current OCF Margin % of 18.26% is 211.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Bio-Rad Laboratories and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 5.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Rad Laboratories's current OCF Margin % is 18.26%, which is 15% above median its own 10-year median of 15.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (BIO.B) is currently considered Fairly Valued. The stock's GF Value™ is $317.48, compared to a current price of $296.49 — trading 6.6% below its estimated fair value. The current OCF Margin % is 18.26%, which is 15% above median its 10-year median of 15.89 and 211.6% above the Medical Devices & Instruments industry median of 5.86. Bio-Rad Laboratories' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Bio-Rad Laboratories (BIO.B), the current OCF Margin % is 18.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Rad Laboratories (BIO.B) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be undervalued.
The current stock price of $296.49 is trading 6.6% below its estimated GF Value™ of $317.48.
GuruFocus considers Bio-Rad Laboratories to be Fairly Valued.
Key valuation signals for BIO.B:
OCF Margin %: 18.26% (15% above median its 10-year median of 15.89)
GF Value™: $317.48 vs. price of $296.49 (6.6% below fair value)
Industry Position: 211.6% above the Medical Devices & Instruments median (#179 of 815)
No single metric tells the full story. See the BIO.B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
71GF Score
Get the complete analysis for BIO.B
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIO.B has been successfully added to your 
